Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study showed that blockade of the CXCR4-CXCL12 axis by ulocuplumab is safe with acceptable AEs and leads to a high response rate in combination with lenalidomide and dexamethasone in patients with relapsed/refractory myeloma, making CXCR4 inhibitors a promising class of antimyeloma drugs that should be further explored in clinical trials.
|
31672767 |
2020 |
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In contrast, MM cells cultured on MM-MSCs' ECM displayed activated MAPK/TI, proliferation, EMT, and CXCR4 (↑15%-250%, P < 0.05).
|
30738861 |
2019 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report that the CXCR4 inhibitor AMD3100 induces disruption of the interaction of MM cells with the BM reflected by mobilization of MM cells into the circulation in vivo, with kinetics that differed from that of hematopoietic stem cells.
|
19139079 |
2009 |
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
F50067, a humanized anti-CXCR4 IgG1 antibody, has promising preclinical activity in MM.We present a phase I multicenter escalation study in relapsed/refractory MM (RRMM) to determine the maximum tolerated dose (MTD) for F50067 alone and in combination with lenalidomide and low dose dexamethasone (Len-Dex).
|
29844860 |
2018 |
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Sensitivity of MM cell lines and primary CD138+ cells from MM patients to panobinostat correlated with reduced expression of the chemokine receptor CXCR4, whereas overexpression of CXCR4 in MM cell lines increased their resistance to panobinostat.
|
31325448 |
2019 |
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD49d, CD44, and CD184, are highly expressed in PCM.
|
23450831 |
2014 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
AMD3100 (plerixafor), a small molecule that selectively inhibits the chemokine receptor CXCR4 is approved for mobilization in combination with G-CSF in patients with Non-Hodgkin's lymphoma and multiple myeloma.
|
27905003 |
2017 |
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
All patients with the CXCR4 T allele and 16 out of 48 with wild type genotype presented with grade III of MM according to the International Staging System (ISS) (p=0.047).
|
23711392 |
2013 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation.
|
26190113 |
2015 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, we propose that inhibition of the CXCR4-SDF-1alpha axis may provide an effective means of treatment for MM-induced osteolysis.
|
15753365 |
2005 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The α4β1-dependent myeloma cell adhesion is up-regulated by the chemokine CXCL12, and pharmacological blockade of the CXCL12 receptor CXCR4 leads to defective myeloma cell homing to bone marrow (BM).
|
22711564 |
2013 |
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our findings indicate that thalidomide therapy induces down-regulation of CXCR4 and its ligand SDF-1alpha in multiple myeloma.
|
18976811 |
2009 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study assessed the diagnostic performance of the CXCR4-directed radiotracer [<sup>68</sup>Ga]Pentixafor in MM and a potential role for stratifying patients to CXCR4-directed therapies.
|
28042328 |
2017 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data demonstrate BTK and cell-surface CXCR4 association in myeloma cells and that BTK plays a role in myeloma cell homing to bone and myeloma-induced bone disease.Am.J. Hematol.88:463-471, 2013.
|
23456977 |
2013 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FTY720 in combination with bortezomib demonstrates superior tumor growth inhibition and abrogates bortezomib-induced CXCR4 increase on MM cells.<b>Conclusions:</b> Altogether, our work identifies a cross-talk between the S1P and CXCR4 pathways in MM cells and provides a preclinical rationale for the therapeutic application of FTY720 in combination with bortezomib in patients with MM.<i></i>.
|
27697999 |
2017 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data demonstrated that hypoxic stimulation in MM cell lines induced the overexpression of lncH19, which, in turn, is required for the expression of the hypoxia induced genes involved in MM dissemination, such as C-X-C Motif Chemokine Receptor 4 (CXCR4) and Snail.
|
30781795 |
2019 |
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Importantly, buparlisib enhanced MM cell mobilization in vivo which was driven by decreased adhesion of MM cells to BMSCs and increased chemotaxis via up-regulation of CXCR4 expression.
|
25060991 |
2014 |
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We functionally overexpressed integrin-α8 in MM cell lines, and surprisingly, stemness features including HIF1α, VEGF, OCT4, and Nanog, as well as epithelial mesenchymal transition (EMT)-related phenotypes, including N-cadherin, Slug, Snail and CXCR4, were induced.
|
28008160 |
2016 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The chemokine (CXCR-4) receptor analogues are the newer agents being postulated for myeloma imaging and have shown good diagnostic performance.
|
30985424 |
2019 |
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Peripheral and marrow iDCs from MM showed high CXCR4 expression and were augmented in bone marrow of MM patients with respect to monoclonal gammopathy of undetermined significance.
|
21569821 |
2011 |
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The decrease tumorigenicity correlated with a "more normal" PC immunophenotype in patients with MM and correlated with CD45 expression and a stronger expression of CXCR4.
|
31534632 |
2019 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have recently reported promising first-in-man experience with CXCR4-directed endoradiotherapy (ERT) in multiple myeloma (MM).
|
28529638 |
2017 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plerixafor (P), an agent that selectively and reversibly binds to the chemokine receptor CXCR4, has been approved in combination with G-CSF (P + G-CSF) for stem cell (SC) mobilization in patients with multiple myeloma (MM).
|
27735212 |
2017 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using four bona fide myeloma cell lines (KHM-1B, KMS12-BM, RPMI8226 and U266) and primary myeloma cells, we identified CD29 (beta1-integrin), CD44, CD49d (alpha4-integrin, a subunit of VLA-4), CD54 (intercellular adhesion molecule-1 (ICAM-1)), CD138 (syndecan-1) and CD184 (CXC chemokine receptor-4 (CXCR4)) as major adhesion molecules expressed on MM. shRNA-mediated knockdown of CD49d but not CD44, CD54, CD138 and CD184 significantly reversed CAM-DR of myeloma cells to bortezomib, vincristine, doxorubicin and dexamethasone.
|
18850009 |
2009 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study, therefore, demonstrates that SDF-1/CXCR4 is a critical regulator of MM homing and that it provides the framework for inhibitors of this pathway to be used in future clinical trials to abrogate MM trafficking.
|
17119115 |
2007 |